TCIM
ICPT

TIAA CREF Investment Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

TIAA CREF Investment Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$4.48M Sell
40,070
-40,337
-50% -$4.41M ﹤0.01% 1524
2018
Q4 		$8.1M Sell
80,407
-1,596
-2% -$165K 0.01% 1054
2018
Q3 		$10.4M Sell
82,003
-7,738
-9% -$819K 0.01% 1083
2018
Q2 		$7.53M Buy
89,741
+29,883
+50% +$2.19M 0.01% 1325
2018
Q1 		$3.68M Sell
59,858
-2,353
-4% -$142K ﹤0.01% 1759
2017
Q4 		$3.63M Sell
62,211
-2,799
-4% -$177K ﹤0.01% 1807
2017
Q3 		$3.77M Sell
65,010
-189
-0.3% -$20.4K ﹤0.01% 1795
2017
Q2 		$7.89M Buy
65,199
+1,624
+3% +$188K 0.01% 1290
2017
Q1 		$7.19M Sell
63,575
-2,160
-3% -$252K 0.01% 1345
2016
Q4 		$7.14M Buy
65,735
+22,426
+52% +$2.67M 0.01% 1358
2016
Q3 		$7.13K Buy
43,309
+3,100
+8% +$489K ﹤0.01% 1356
2016
Q2 		$5.74M Sell
40,209
-88
-0.2% -$12.8K ﹤0.01% 1433
2016
Q1 		$5.18M Sell
40,297
-14,056
-26% -$1.66M ﹤0.01% 1487
2015
Q4 		$8.12M Sell
54,353
-35,335
-39% -$5.98M 0.01% 1205
2015
Q3 		$14.9M Sell
89,688
-6,137
-6% -$1.35M 0.01% 848
2015
Q2 		$23.1M Buy
95,825
+34,878
+57% +$9.29M 0.02% 734
2015
Q1 		$17.2M Buy
60,947
+22,144
+57% +$4.8M 0.01% 847
2014
Q4 		$6.05M Sell
38,803
-3,562
-8% -$658K ﹤0.01% 1488
2014
Q3 		$10M Buy
42,365
+8,668
+26% +$2.21M 0.01% 1094
2014
Q2 		$7.97M Sell
33,697
-8,056
-19% -$2.12M 0.01% 1343
2014
Q1 		$13.8M Sell
41,753
-214,335
-84% -$72.3M 0.01% 961
2013
Q4 		$17.5M Buy
256,088
+71,418
+39% +$4.13M 0.01% 848
2013
Q3 		$12.7M Buy
184,670
+159,599
+637% +$7.88M 0.01% 951
2013
Q2 		$1.12M Buy
+25,071
New +$857K ﹤0.01% 2511

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TIAA CREF Investment Management's ICPT Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Intercept Pharmaceuticals, Inc. (ICPT) stake by 50% in Q1 2019, selling an estimated $4.41M and leaving 40,070 shares worth $4.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1524.

TIAA CREF Investment Management first reported a position in ICPT in Q2 2013 and has held it in 24 quarters since. The position peaked at $23.1M in Q2 2015. 202 funds tracked by Wall St. Rank hold ICPT as of Q1 2019.

  • TIAA CREF Investment Management held 40,070 shares of Intercept Pharmaceuticals, Inc. worth $4.48M as of Q1 2019.
  • TIAA CREF Investment Management sold 40,337 Intercept Pharmaceuticals, Inc. shares in Q1 2019, an estimated $4.41M.
  • Intercept Pharmaceuticals, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1524 holding.
  • TIAA CREF Investment Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Intercept Pharmaceuticals, Inc. position peaked at $23.1M in Q2 2015.
  • 202 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.